We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mylan Will Outlicense Nebivolol, Buy Back $1.25 Billion in Stock
Mylan Will Outlicense Nebivolol, Buy Back $1.25 Billion in Stock
June 14, 2005
Mylan Laboratories is seeking a licensee for its highly anticipated beta-blocker nebivolol and could select a partner as early as this fall, company officials said during a June 14 conference call.